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Objectives: To study the incidence, clinical manifestations, concomitant conditions and case-fatality rate in patients 
with invasive group B Streptococcus (GBS) infections in the Goteborg area (mean population 582 666) of Sweden 
during 1981-95. 
Design: Patients were identified from the records of the Department of Clinical Bacteriology. Clinical data were 
obtained from hospital records. 
Results: GBS was isolated from blood, cerebrospinal fluid or other sterile body fluids from 211 patients with 215 
infectious episodes; 108 in neonates, and 107 in non-neonates. The incidence was 2.4/100 000 per year, with the highest 
rates in neonates and in persons 265 years. The incidence in neonates was 0.92/1000 live births. The most common 
manifestation was septicemia with unknown focus. Of the neonates, 54% were full term and had no underlying 
conditions. Of the non-neonates, 15% had no underlying conditions. The most common underlying conditions were 
preterm delivery in neonates, and arteriosclerotic disease and diabetes mellitus in non-neonates. The case-fatality 
rates were 13% in neonates and 16% in non-neonates. 
Conclusions: GBS is an important pathogen in neonates and in adults with concomitant conditions. The morbidity 
and mortality rates necessitate research to develop GBS vaccines both for women of fertile age and for patients with 
a wide variety of underlying diseases. 
Int J Infect Dis 2003; 7: 113-119 
INTRODUCTION 
Until the early 1960s Streptococcus agalactiae or the 
group B Streptococcus (GBS) was mainly known as a 
cause of bovine mastitis.l During the late 1960s and early 
1970s the organism, for unknown reasons, emerged as 
the leading cause of sepsis and meningitis in neonates in 
North America and many countries in western Europe.2-6 
Although most of the literature on GBS infections 
concerns infections in neonates and pregnant women, 
infections in older children and adults, most of whom 
have underlying disorders, have also been described.7-9 
It is possible that vaccines against GBS infections will 
be available in the future.lO Because of the changes in 
GBS epidemiology over time and differences between 
countries and populations, it is important to contin- 
uously survey GBS infections. 
The aims of the present retrospective study were 
to estimate the incidence of invasive GBS infections in 
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different age groups and to define risk groups in a 
defined area around Goteborg in western Sweden. 
MATERIALS AND METHODS 
In a retrospective study, patients with invasive GBS 
infections during 1981-95, living in Goteborg and the 
surrounding communities Harryda, Kungalv, Miilndal, 
Partille and acker8 in southwestern Sweden, were 
identified. Patients were included if S. agalactiae was 
isolated from normally sterile body fluids: amniotic fluid, 
blood, bursal fluid, cerebrospinal fluid (CSF), pleural 
fluid, peritoneal fluid, or synovial fluid. 
The patients were identified from the files of the 
Department of Clinical Bacteriology in Goteborg, which 
serves all hospitals in the study area. 
In total, 214 patients with 218 episodes of invasive 
infection living in the study area were found.The records 
of three patients (1.4%) could not be found. 
Demographic data were obtained from official 
statistics. The population in the study area increased 
during the 15-year study period from 567 199 to 612 012. 
The numbers of blood cultures analyzed at the 
laboratory ranged between 15 510 and 19 168 per year, 
with no tendency to increase during the study period. 
The numbers of CSF cultures ranged between 1174 and 
2074 per year, with the same kind of irregular variation. 
Very early-, early- and late-onset infections were 
defined as infections with onset of symptoms ~24 h, 
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l-6 days and 7-27 days after birth, respectively. Very 
late-onset infections were defined as infections with 
onset of symptoms between 28 days after birth through 
a gestational age of 46 weeks, counted from the first day 
of last menstruation. 
Alcoholism was considered to be an underlying 
condition when the abuse was ongoing or periodic. 
Information about smoking was often lacking and was 
therefore not included among underlying conditions. 
Atherosclerotic disease was considered to be an under- 
lying condition in patients who had at least two of the 
following diagnoses: atria1 fibrillation, coronary heart 
disease with or without previous myocardial infarction, 
heart failure, hypertension, stroke, or intermittent 
claudication. Previous surgery was considered to be an 
underlying condition in patients who had undergone 
surgery within the last 3 weeks, or if the operation had 
caused a locus minoris, e.g. impaired blood circulation. 
In non-neonates, an infection was arbitrarily defined as 
hospital acquired if the patient had spent 7 days or more 
in the hospital before onset of symptoms. 
Trends over time in incidence rates were tested with 
logistic regression models (which give the same results 
as a Poisson regression model, as the number of cases is 
small compared to non-cases). Proportions were com- 
pared with Fisher’s exact test. 
The study was approved by the Ethics Committee, 
Gdteborg University. 
RESULTS 
Incidence 
Table 1 shows the sources of isolates of the first in- 
fectious episodes in the 211 patients with invasive GBS 
infections whose records were found. Only two patients 
had two and four GBS infections, respectively, on 
separate occasions. Table 2 shows the total incidence of 
all invasive GBS infections during three 5-year periods. 
The tendency for increased incidence was not significant. 
The incidence over the whole 15-year period was 
2.4/100 000 per year. 
Age distribution 
Tables 3 and 4 show the age distribution and age-specific 
incidence rates. The highest incidence was seen in neo- 
nates, followed by individuals 65 years and older. Only 
four cases were found in children beyond the neonatal 
period and adolescents. 
One hundred and eight (51%) of the 211 patients 
were neonates. Table 4 shows the incidence in neonates 
during three 5-year periods. The incidence increased 
significantly (P=O.O42) when the three 5-year periods 
were compared. The incidence in neonates was 0.92/1000 
live births during the 15year period. 
Sex distribution 
One hundred and fourteen patients (54%) were male. 
The overall male/female ratio was 1.2 : 1. The male/female 
ratio in neonates was 1.2: 1, and that in non-neonates 
was 1.1: 1. 
Clinical manifestations 
Tables 5 and 6 show the main clinical manifestations in 
neonates and non-neonates, respectively, with invasive 
GBS infections. For patients with more than one mani- 
festation during the same infectious episode, only the 
most severe is included. 
In neonates, septicemia with unknown focus was the 
predominant manifestation (71%), and meningitis was 
the second most common (15%). 
In non-neonates, the clinical picture was more varied. 
Septicemia with unknown focus was the most common 
manifestation in this group also, but was less common 
than in neonates (40% versus 71%, P<O.OOOOl). Cellu- 
Table 1. Sources of group 6 streptococcal isolates in normally 
sterile body fluids from 211 patients with group B streptococcal 
infections 
Body fluid 
No. of episodes 
for which data 
were JVJi/Jb/e 
Blood 178 
Blood+CSF 18 
CSF 2 
Blood+synovial fluid 3 
Synovial fluid 5 
Blood+amniotic fluid 1 
Blood+perioperative hip fluid 1 
Pleural fluid 2 
Peritoneal fluid 1 
Total 211 
Table 2. Documented incidence (no. of cases per 100000 inhabitants per year) of invasive GBS infections in the Goteborg area of 
Sweden 1981-95 
Period 
1981-85 
1986-90 
1991-95 
Tota I 
MeJn pOpU/JtiOn 
567 372 
581744 
598 881 
582 666 
Meningitis Other infections 
No. of cases Incidence No. of cases Incidence 
7 0.2 53 1.9 
9 0.3 63 2.2 
8 0.3 71 2.4 
24 0.3 187 2.1 
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Table 3. Total and age-specific incidence (no. of cases per 100000 inhabitants per year) of invasive GBS disease in the Giiteborg 
area of Sweden 1981-95 
Age (years) Mean population 
o-4 36062 
5-9 31546 
IO-19 67608 
20-29 65771 
30-39 94015 
40-49 88462 
50-59 60844 
60-64 30237 
65-69 29132 
70-74 26466 
275 43635 
All 582 666 ages 
Meningitis Other infections 
No. of cases Incidence No. of cases Incidence 
19 3.5 93 17.2 
0 0.0 0 0.0 
0 0.0 0 0.0 
0 0.0 8 0.8 
0 0.0 6 0.4 
2 0.2 6 0.5 
0 0.0 7 0.8 
1 0.2 5 1.1 
0 0.0 16 3.7 
2 0.5 20 5.0 
0 0.0 26 4.0 
24 0.3 187 2.1 
Incidence of 
all infections 
20.7 
0.0 
0.0 
0.8 
0.4 
0.6 
0.8 
1.3 
3.7 
5.5 
4.0 
2.4 
Table 4. Documented incidence (no. of cases per 1000 live births) of invasive GBS infections in neonates in the Gateborg area of 
Sweden, 1981-95 
Total number 
Period of live births 
1981-85 34118 
1986-90 41186 
1991-95 42332 
Total 117636 
Meningitis Other infections 
No. of cases Incidence No. of cases Incidence 
4 0.12 20 0.59 
6 0.15 30 0.73 
6 0.14 42 0.99 
16 0.14 92 0.78 
Incidence of 
all infections 
0.70 
0.87 
1.13 
0.92 
Table 5. Principal clinical manifestations in 108 neonates with invasive GBS infections 
Clinical manifestations 
Septicemia, unknown focus 
Pneumonia 
Meningitis 
Chorioamnionitis 
Tota I 
Very early Early Late Very late 
onset onset onset onset 
62 11 4 0 
11 3 0 0 
3 5 4 4 
1 0 0 0 
77 19 8 4 
Total 
77 
14 
16 
1 
108 
litis, endocarditis and pneumonia were other common 
manifestations, each constituting lo-12% of all cases. 
Underlying conditions 
Tables 7 and 8 show gestational age and underlying con- 
ditions in the 108 neonates with invasive GBS infections. 
Of the 31 preterm neonates (29%), nine had another 
underlying condition besides preterm delivery. Of the 76 
full-term neonates (70%), 18 had another underlying 
condition. The only post-term neonate also had under- 
lying conditions-intrauterine asphyxia and aspiration 
of meconium. Thus, of all 108 infected neonates, 58 
(54%) were full term and had no underlying condition. 
Of these 58 neonates, 35 (60%) had very early-onset 
infection, 14 (24%) had early-onset infection, five had 
late-onset infection, and four had very late-onset infect- 
ion. No case of vertical transmission was found. 
Of the non-neonates, at least 85% (M/103) had an 
underlying condition (Table 9). A wide variety of under- 
lying conditions was seen, and some patients had more 
than one disease. The most common underlying condi- 
tions were arteriosclerotic disease and diabetes mellitus, 
reflecting the higher age of the patients. 
In non-neonates, 25 of 103 (24%) infectious episodes 
were hospital acquired. Of those, not less than 20 occur- 
red in patients aged 65 years or more. 
Case-fatality rate 
The overall case-fatality rate was 14% (30 of 211 patients; 
Table 10). The case-fatality rate was high in neonates, 
was low during early adulthood, and increased there- 
after with age. 
The case-fatality rate in neonates with a known 
underlying condition was 6128 (21%), compared to 8/80 
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Table 6. Principal clinical manifestations in 103 non-neonates with invasive GBS infections 
Clinical presentation 514 years 15-29 years 30-64 years 265 years Total 
Septicemia, unknown focus 0 
Pneumonia/pleural empyema 0 
Meningitis 3 
Cellulitis 0 
Endocarditis 0 
Arthritis 0 
Endometritis 0 
Pyelonephritis 1 
Osteomyelitis 0 
Sinusitis 0 
Bursitis and cellulitis 0 
Subphrenic abscessa 0 
Salpingitis 0 
Tota I 4 
8 32 
2 8 
3 2 
1 10 
4 6 
6 1 
0 0 
1 1 
0 2 
1 0 
0 1 
0 1 
1 0 
27 64 
41 
11 
8 
11 
12 
8 
3 
3 
2 
1 
1 
1 
1 
103 
aPneumonia also. 
Table 7. Gestational age of 108 neonates with invasive GBS 
infection, 1981-95 
Number of episodes in 
indicated age groups 
Gestational Very early Early Late Very late Total no. 
age (weeks) onset onset onset onset of episodes 
25-26 1 0 0 1 (1) 
27-28 2 0 0 2 (2) 
29-30 1 0 0 1 (0) 
31-32 6 0 0 6 (4) 
33-34 8 1 0 11 (2) 
35-36 7 2 1 0 10 (2) 
37-38 12 5 1 3 21 (2) 
39-40 22 7 4 1 34 (1) 
41-42 17 3 1 0 21 (0) 
43-44 1 0 0 0 1 (0) 
Numbers in parentheses indicate number of patients who died. 
(10%) in neonates with no known underlying condition 
(non-significant). 
In non-neonates, the case-fatality rate for those with 
a known underlying condition was 15/88 (17%), and for 
those without an underlying condition it was l/15 (6.6%) 
(non-significant). 
There was a wide range of variation in underlying 
conditions in the patients who died, and no major differ- 
ences compared to those who survived. 
Of the 30 patients who died, 15 (50%) died within 
24 h of admittance to hospital or within 24 h of onset of 
symptoms (for hospital-acquired infections). Thirteen 
(87%) of the patients who died within 24 h were neo- 
nates. 
Table 8. Principal underlying conditions in 108 neonates with invasive GBS infections 
Number of episodes in indicated age group 
Underlying conditions 
Very early 
onset 
Pre- Full- 
term term 
Early 
onset 
Pre- Full- 
term term 
Late 
onset 
Pre- Full- 
term term 
Very late 
onset 
Pre- Full- 
term term 
Total number 
of episodes 
Pre- Full- 
term term 
Maternal infection predelivery 0 9 0 
Intrauterine asphyxia 2 5a 0 
Twins (twin birth) 3 0 1 
Premature rupture of 
the membranes 3 1 0 
Maternal diabetes mellitus 0 4 0 
Extrauterine asphyxia 0 1 0 
Small for gestational age 0 0 0 
Maternal toxicosis 0 1 0 
Meconium aspiration 0 I= 0 
Congenital heart disease 0 0 0 
Chromosomal aberration other 
than Down’s syndrome 1 0 0 
Congenital atresia of jejunum 1 0 0 
Total no. of episodes 10 22 1 
Patients with one or more 
underlying conditions 8 17 1 
Patients with no known 
underlying condition 17 35 3 
Numbers in parentheses indicate number of patients who died. 
aOne neonate was post-term and had two underlying conditions. 
1 0 0 0 0 0 (0) 10 (0) 
0 0 0 0 0 2 (I) 5a (I) 
0 0 1 0 0 4 (1) 1 03 
0 0 0 0 0 3 (3) 1 (0) 
0 0 0 0 0 0 (0) 4 (0) 
0 0 0 0 0 0 (0) 1 (0) 
0 0 1 0 0 0 (0) 1 (0) 
0 0 0 0 0 0 (0) 1 (0) 
0 0 0 0 0 0 (0) I= (0) 
0 0 1 0 0 0 (0) 1 (0) 
0 0 0 0 0 1 (0) 0 (0) 
0 0 0 0 0 1 (0) 0 (0) 
1 0 3 0 0 11 (5) 26 (2) 
1 0 1 0 0 9 (5) 19 (1) 
14 2 5 0 4 22 (6) 58 (2) 
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Table 9. Principal underlying conditions in 103 non-neonates with invasive GBS infections 
No. of episodes in indicated age group 
Underlying conditions 5 14 years 15-29 years 30-64 years 2 65 years 
Alcoholism 0 0 3 4 
Drug abuse 0 0 1 0 
Asthma or chronic obstructive 
pulmonary disease” 0 0 0 1 
Malignant lung tumora 0 0 0 1 
Arteriosclerotic disease 0 0 4 21 
Diabetes mellitus 0 0 1 22 
Hematologic or lymphopoietic 
malignancy 0 0 2 6 
Autoimmune disease 0 0 1 6 
Other malignancy 0 0 3 9 
Pregnancy 0 5 3 0 
Recent operationb 0 2 3 11 
Chronic woundC 0 0 0 7 
Splenectomy 0 0 1 0 
Benign monoclonal gammopathy 0 0 0 1 
Neurologic disease 0 0 1 2 
Renal disease, not dialysis- 
dependent 1 0 1 0 
Injury to head/leakage of CSFd 0 0 0 1 
Hepatic disease, alcohol-associated 0 0 1 2 
Hepatic disease, not alcohol- 
associated 0 0 0 1 
AIDS 0 0 0 1 
Chronic inflammatory bowel disease 0 0 1 0 
Other conditio& 0 1 5 4 
Patients with one or more 
underlying conditions 1 8 21 58 
Patients with no known 
underlying condition 3 0 6 6 
Numbers in parentheses indicate number of patients who died. 
“Only noted for patients with pneumonia. 
bFor instance, abortion, dilation of urethra, lymph node extirpation, cystoscopy. 
CDue to circulation problems e.g. diabetes or after vein thrombosis. 
dOnly noted in patients with meningitis. 
eSevere obesity, history of rheumatic fever, post-traumatic, other lung disease, myelomeningocele, or neurodermatitis. 
Total no. of episodes 
7 (1) 
1 (0) 
1 (I) 
1 (0) 
25 (8) 
23 (3) 
8 (2) 
7 (I) 
12 (1) 
8 (0) 
16 (0) 
7 (0) 
1 (0) 
1 (0) 
3 (I) 
2 (1) 
1 (0) 
3 (1) 
1 (I) 
1 (1) 
1 (0) 
10 (0) 
88 (15) 
15 (1) 
Table 10. Case-fatality rate in invasive GBS infections in 
different age groups 
Age group 
Neonates 
Non-neonates 
514 years 
15-29 years 
30-64 years 
265 years 
Total 
No. of 
patients 
108 
4 
8 
27 
64 
211 
Total percentage 
No. of of deaths in 
deaths age group 
14 13.0 
0 0 
0 0 
4 14.8 
12 18.8 
30 
Multiple infections 
Two patients had more than one episode of invasive 
GBS infection. The first was a preterm neonate with a 
very late-onset infection (meningitis) who had a second 
GBS infection (septicemia with unknown focus) at the 
age of 4 months. He had no known underlying condition. 
The second patient, an %-year-old woman, had four 
episodes of cellulitis with bacteremia within 7 months. 
After that, she was given continuous antibiotic prophy- 
laxis. She had impaired circulation secondary to a deep 
venous thrombosis, and also arteriosclerotic disease. 
Only the first infectious episode of these two patients is 
included in all tables. 
DISCUSSION 
The present study shows that invasive GBS infections in 
Sweden constitute an important clinical problem in two 
patient groups, neonates with and without underlying 
conditions and non-neonates with severe underlying 
diseases. Although the incidence is around loo-fold 
higher in neonates than in other age groups, the total 
number of documented cases was similar in neonates 
and in non-neonates in the present study. It must be 
emphasized that the documented incidence in this and 
other retrospective studies gives a minimum figure for 
incidence, because blood cultures may not always be 
obtained in febrile patients with bacteremia. It is our 
personal impression, from several years of clinical work 
at hospitals in the area studied, that blood cultures in 
neonates with a suspicion of sepsis usually are obtained 
(but only one culture per infectious episode and often 
with a suboptimal amount of blood). Blood cultures in 
febrile patients after the neonatal period are often 
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omitted. Thus, the true incidence of GBS infections is 
probably higher than the documented incidence in both 
neonates and non-neonates, which has also been 
suggested by another study in which both blood cultures 
and urine antigen test were performed on neonates with 
symptoms of GBS infections.ll During the time period 
studied, screening of pregnant women for carriage of 
GBS was not routinely performed. Intrapartum prophy- 
laxis for GBS was given to mothers with identified 
obstetric risk factors (e.g. premature rupture of the 
membranes) and for newborns at risk without clinical 
symptoms (e.g. if the mother had a previous child with 
an invasive GBS infection). Thus, we believe that very 
few cases of GBS infection in neonates were prevented 
by this policy. 
The documented incidence of invasive GBS infect- 
ions in the present study, 0.92/1000 live births, is similar 
to the incidence found in a study from the same area of 
all neonatal invasive infections covering the time period 
1975-866 (partly overlapping with the present study). 
Thus, the incidence has remained stable but with a ten- 
dency to increase over a 21-year period. Recent studies 
from other European countries have shown varying 
incidence figures, from 0.4 to 5.4 cases per 1000 live 
births.12-is In agreement with many other studies, the 
present study shows that invasive GBS infections are 
common in preterm neonates and in neonates with 
underlying conditions (46% of all cases in the present 
study), and that very early and early infections dominate 
(84% of all cases in the present study).1-6,12-18 The case- 
fatality rate in neonates is still high (13% in the present 
study), partly due to low gestational age of the patients 
and partly due to the fulminant course of many infec- 
tious episodes. 
Invasive GBS infections in children after the 
neonatal period7 and in adults have been documented 
but less thoroughly studied than infections in neo- 
nates.8.9.19-22 The present study showed an incidence of 
about 1.181100000 inhabitants per year after the neo- 
natal period, which is about 10 times lower than the 
incidence of invasive pneumococcal infections according 
to a study performed concurrently with the present one 
in the same area during the same time period.23 Other 
population-based studies of invasive GBS infections 
after the neonatal period have shown similar or higher 
incidence rates, varying between 2.4 and 5.9 cases per 
100 000 per year.8,9,22~24~25 
The present study shows that there are many 
similarities between invasive GBS infections and in- 
vasive pneumococcal infections in non-neonates; for 
example, both infections are mainly seen in patients with 
a wide variety of underlying conditions and in the 
elderly. GBS must, however, not be forgotten in other- 
wise healthy individuals, since 15% of the non-neonates 
in the present study had no known predisposing 
condition. It is remarkable that only five non-neonates 
younger than 20 years were found in the present study, 
while the number of invasive pneumococcal infections 
in the same age group was 102.23 Other important differ- 
ences between invasive GBS and pneumococcal infect- 
ions were that alcoholism is the most important risk 
factor in pneumococcal infections, while it was rather 
uncommon in GBS infections, and that pneumonia was 
by far the most common clinical manifestation of 
pneumococcal infections, while septicemia of unknown 
origin dominated in GBS infections. This is similar to 
findings in other studies. 8,22 The case-fatality rate in 
invasive GBS infections in non-neonates was as high 
as 16%, which was similar to the case-fatality rate in 
invasive pneumococcal infections.23 Other studies have 
shown similar or even higher case-fatality rates in 
invasive GBS infections.8,20,22 A high proportion of those 
who died in this study (50%) did so within 24 h after 
onset of symptoms or within 24 h after arrival in 
hospital, and were probably beyond rescue. Among 
these 15 patients, however, only two (13%) were non- 
neonates, compared to 30 of 136 (22%) non-neonates 
with invasive pneumococcal infections during the same 
study period. 23 This fulminant course of many invasive 
GBS infections emphasizes the need for preventive 
measures, e.g. vaccines. 
Infections with HIV, a recently recognized risk 
factor for invasive bacterial infections,8,26-29 emerged 
during the course of the present study. In total, 348 HIV- 
infected patients were reported between 1985 and 1995 
in the study area. This had, however, almost no impact 
on the total burden of invasive GBS infections: one 
documented case during 15 years. 
In the present study, we found only two patients 
who had multiple invasive GBS infections, one neonate 
and one non-neonate. A previous study documented 
that 4% of the adults with invasive GBS infections had 
multiple GBS infections. 3o It is not possible from these 
sparse data to draw any conclusions about whether they 
were infected with strains of different serotypes or the 
same serotype. 
In conclusion, the study confirms the importance 
of invasive GBS infections in both neonates and non- 
neonates, and the true incidence rates are probably 
considerably higher than the incidence rates docu- 
mented in the present and other retrospective studies. 
If conjugated GBS polysaccharide vaccines or vaccines 
based on surface proteins become available, women of 
fertile age will constitute an obvious target group for 
vaccination,10z31,32 even though preterm neonates who 
have an increased risk of GBS infections may be less 
well protected by this vaccination.33-35 Furthermore, 
patients with a wide variety of underlying conditions 
should be considered for vaccination, and the guidelines 
might be similar to those issued for the use of the pneu- 
mococcal polysaccharide vaccine.36 
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